Icovamenib
Based on 1 Customer Validation
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes.
For research use only. We do not sell to patients.
- Purity: 98.96%
- CAS No.: 2448172-22-1
- Formula: C31H34N8O3
- Molecular Weight:566.65
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures, in a concentration- and glucose-dependent manner[2].
Icovamenib shows potent cytotoxicity on various menin-dependent acute myeloid leukemia (AML) cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2448172-22-1
-
Appearance Solid
-
Molecular Weight 566.65
-
Formula C31H34N8O3
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC(CN2C[C@@H](CCC2)NC(C=C)=O)=CC=N1)NC3=CC=C(C=C3)C4=CC5=C(N6CCOCC6)N=CN=C5N4
-
Synonyms
BMF-219; Menin-MLL inhibitor 21
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 25 mg/mL (44.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 8.33 mg/mL (14.70 mM); Clear solution; Need ultrasonic and adjust pH to 2 with 1 M HCl
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction.WO2020142557 A1.
[3]. Mo J, et al. Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML). Eur J Med Chem. 2025 Jun 12;296:117847. [Content Brief]
[5]. Carraway, H. E., et al., (2025). Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib. Haematologica, 110(4), 1041–1046. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7648 mL | 8.8238 mL | 17.6476 mL | 44.1189 mL |
| 5 mM | 0.3530 mL | 1.7648 mL | 3.5295 mL | 8.8238 mL | |
| 10 mM | 0.1765 mL | 0.8824 mL | 1.7648 mL | 4.4119 mL | |
| 15 mM | 0.1177 mL | 0.5883 mL | 1.1765 mL | 2.9413 mL | |
| 20 mM | 0.0882 mL | 0.4412 mL | 0.8824 mL | 2.2059 mL | |
| 25 mM | 0.0706 mL | 0.3530 mL | 0.7059 mL | 1.7648 mL | |
| 30 mM | 0.0588 mL | 0.2941 mL | 0.5883 mL | 1.4706 mL | |
| 40 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1030 mL |
Icovamenib Related Classifications
HY-150105 Related Classifications
Powered by Bioz